WEBULL
News
IDYA
34.10
+2.53%
0.84
How Investors May Respond To IDEAYA Biosciences (IDYA) Regaining Oncology Programs After GSK Collaboration Exit
Simply Wall St · 1d ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 3d ago
IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress
Simply Wall St · 3d ago
Weekly Report: what happened at IDYA last week (1208-1212)?
Weekly Report · 4d ago
Ideaya Biosciences Advances with IDE892 Study Targeting MTAP-Deleted Tumors
TipRanks · 5d ago
IDEAYA Biosciences Faces Collaboration Termination by GSK
TipRanks · 6d ago
Citi places Ideaya on ‘upside 90-day catalyst watch’ into data
TipRanks · 12/12 14:46
Promising Outlook for IDEAYA Biosciences: Buy Rating Backed by Positive Trial Expectations
TipRanks · 12/12 14:45
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Amylyx Pharmaceuticals Inc (AMLX) and PACS Group Inc (PACS)
TipRanks · 12/12 12:40
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma
NASDAQ · 12/11 12:24
Ideaya Biosciences completes enrollment in OptimUM-02 trial
TipRanks · 12/11 11:12
Ideaya Biosciences Completed Its Targeted Full Enrollment of 435 Patients In Phase 2/3 OptimUM-02 Trial of Darovasertib Combined With Pfizer's Crizotinib for HLA*A2-Negative Metastatic Uveal Melanoma; Median Progression-free Survival Data is Expected in Q1 2026
Benzinga · 12/11 11:08
IDEAYA Biosciences Completes Enrollment in Pivotal Phase 2/3 Trial of Darovasertib and Crizotinib for Metastatic Uveal Melanoma
Reuters · 12/11 11:00
IDEAYA BIOSCIENCES INC - TOPLINE DATA EXPECTED IN 1Q 2026
Reuters · 12/11 11:00
IDEAYA BIOSCIENCES COMPLETES TARGETED FULL ENROLLMENT IN RANDOMIZED PIVOTAL PHASE 2/3 TRIAL (OPTIMUM-02) OF DAROVASERTIB IN COMBINATION WITH CRIZOTINIB IN FIRST-LINE HLA*A2-NEGATIVE METASTATIC UVEAL MELANOMA
Reuters · 12/11 11:00
IDEAYA Biosciences: Promising Future with Innovative Dual KAT6/7 Inhibitor and Strong Financial Position
TipRanks · 12/10 13:05
Ideaya Biosciences submits IDE574 IND application to FDA
TipRanks · 12/10 11:05
IDEAYA Biosciences Submits FDA Application for First-in-Class KAT6/7 Dual Inhibitor IDE574, Targets Early 2026 Trials
Benzinga · 12/10 11:04
IDEAYA BIOSCIENCES ANNOUNCES IND SUBMISSION FOR IDE574, A POTENTIAL FIRST-IN-CLASS KAT6/7 DUAL INHIBITOR FOR BREAST AND LUNG CANCERS
Reuters · 12/10 11:00
IDEAYA BIOSCIENCES INC - PRECLINICAL DATA FOR IDE574 TO BE PRESENTED IN 1H 2026
Reuters · 12/10 11:00
More
Webull provides a variety of real-time IDYA stock news. You can receive the latest news about Ideaya Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).